The Government launched the CDCC Scheme in November 2023, providing subsidy for the public to conduct screening for and manage targeted chronic diseases, including diabetes mellitus and hypertension, in the private healthcare sector via a "Family Doctor for All" and multidisciplinary public-private partnership model coordinated by District Health Centres / District Health Centre Expresses (collectively referred to as DHC/Es). The CDCC Scheme has been further expanded to cover blood lipid testing for eligible individuals, allowing for a more comprehensive approach to the assessment and proper management of cardiovascular disease risk factors, including the "three highs" (high blood pressure, high blood sugar and high cholesterol).

The CDCC Scheme aims to facilitate early detection and timely intervention of such chronic diseases and encourage self-health management by the participants of the CDCC Scheme, so as to help them better manage their chronic diseases and prevent complications, as well as reduce the demand for public specialised and hospital services.

In line with the development of the Primary Healthcare Blueprint, the CDCC Scheme will expand its service targets in phases to invite suitable patients currently attending the Family Medicine Clinics (formerly known as General Outpatient Clinics) (FMCs) of the Hospital Authority (HA), and participants of the General Outpatient Clinic Public-Private Partnership Programme (GOPC PPP) which is scheduled to conclude in 2028.



Upon successful enrolment, eligible patients will directly enter the Treatment Phase of the CDCC Scheme, where they will receive the same service arrangement as all other participants, including the number of subsidised consultation visits per year and the co-payment amounts. The co-payment arrangement also applies to HA staff, civil service eligible persons, and other individuals entitled to medical fee waivers when receiving services at HA.

For Eligible Patients from HA FMCs

Patients must fulfil the clinical and eligibility criteria specified by the Government and must have been attending HA FMCs for treatments of diabetes mellitus, hypertension, prediabetes, or dyslipidemia for at least 12 months prior to receiving an invitation.

For Eligible Patients from the GOPC PPP

Patients must be participating in the GOPC PPP and fulfil the clinical and eligibility criteria specified by the Government.

Eligible patients will receive invitation letters in phases to join the Treatment Phase of the CDCC Scheme. Direct enrolments to the Treatment Phase of the CDCC Scheme are by invitations only. Invitations will take place from the latter half of 2025 to 2027, starting with patients from HA FMCs, followed by patients participating in the GOPC PPP shortly after.

The GOPC PPP is planned to conclude in 2028. Starting in 2026, participants in the GOPC PPP will receive invitations in phases to join the CDCC Scheme. They will be given sufficient time to consider whether to participate. During this transition period, patients will continue to receive services under the GOPC PPP.

For Eligible Patients from HA FMCs

After receiving the invitation letters to join the CDCC Scheme, interested HA FMC patients should complete and mail the reply slips to the HA. The HA will then transfer the case summaries of the interested patients to their selected DHC/Es, who will contact them to arrange a visit to complete the enrolment procedures.

Upon successful enrolment, HA FMC patients will enter the Treatment Phase of the CDCC Scheme directly. HA will cancel their follow-up appointments at HA  FMCs after their first subsidised medical consultations with their family doctors under the CDCC.

HA FMC patients not joining the CDCC Scheme will continue to receive care at their current HA FMCs.

For Eligible Patients from the GOPC PPP

After receiving the invitation letters to join the CDCC Scheme, interested GOPC PPP patients should complete and mail the reply slips to the HA. The HA will then transfer the case summaries of the interested patients to their selected DHC/Es, who will contact them to arrange a visit to complete the enrolment procedures.

Eligible GOPC PPP patients who are interested to enrol in the CDCC Scheme may also do so at the clinic of their family doctors directly, provided that they wish to continue receiving care from the same family doctor after joining the CDCC Scheme, and the family doctor they wish to pair with has enrolled in the CDCC Scheme and supports Scheme Participant enrolment. This arrangement can take place before the patients receive the special invitations from the Programme Office of the CDCC Scheme.

Upon successful enrolment, GOPC PPP patients will enter the Treatment Phase of the CDCC Scheme directly. After receiving their first subsidised medical consultation visits with their paired Family Doctors, they will be withdrawn from the GOPC PPP.

For Eligible Patients from HA FMCs

Eligible HA FMC patients not joining the CDCC Scheme will continue to receive care at their current HA FMCs.

For Eligible Patients from the GOPC PPP

Eligible GOPC PPP patients not joining the CDCC Scheme will continue to receive services under the GOPC PPP until its conclusion. The GOPC PPP is planned to conclude in 2028. The HA will arrange, based on patients’ conditions, for their return to the HA FMCs in phases for continued care prior to the conclusion of the GOPC PPP. Alternatively, GOPC PPP patients may choose to continue their care under the same doctors at their own expense, through private arrangements made independently of the GOPC PPP.

Upon successful enrolment, invited eligible patients will skip the Screening Phase and enter directly into the Treatment Phase of the CDCC Scheme. They will receive medical consultations and medications under the "Specified Drugs" list from family doctors according to their clinical needs. Family doctors may also refer patients for necessary laboratory and other investigation services; as well as dedicated nursing clinic and allied health services under the designated District Health Network.

Eligible HA FMC and GOPC PPP patients joining the Treatment Phase of the CDCC Scheme via special invitations will receive the same service arrangement, including the number of subsidised medical consultation visits per year, as all other participants in the Treatment Phase of the CDCC Scheme. The number of subsidised medical consultation visits per year varies based on the patient diagnoses:

Diabetes mellitus (DM) and/or hypertension (HT)

Patients diagnosed with DM and/or HT are entitled to up to 6 consultations per year, regardless of any additional chronic conditions.

Prediabetes only

Patients diagnosed solely with prediabetes (HbA1c 6.0%–6.4% or FPG 6.1–6.9 mmol/L), without hypertension, are entitled to up to 4 consultations per year.

Dyslipidaemia only

Patients diagnosed solely with the specified condition of dyslipidaemia, without prediabetes, diabetes, or hypertension, are entitled to 4 consultations in the first year, and 2 consultations per year from the second year onward.

Dyslipidaemia with other conditions

Patients diagnosed with dyslipidaemia and conditions such as prediabetes, DM, or HT will have their consultation entitlement determined by whether they have DM or HT. If the patient has prediabetes but does not have DM or HT, the entitlement is 4 subsidised consultations per year. If the patient has DM or HT, the entitlement increases to 6 subsidised consultations per year.

During each subsidised medical consultation visit of the Treatment Phase under the CDCC Scheme, patients will receive management of their chronic illnesses. When receiving treatment for their chronic illnesses, patients may also receive diagnosis and treatment for episodic illnesses during the same subsidised medical consultation visit when required. If patients receive treatment for episodic illnesses only, such is considered outside the scope of the CDCC Scheme and patients have to pay the full costs specified by the family doctors.

Patients participating in the CDCC Scheme are required to pay the co-payments in accordance to the amounts set out in the Co-Payment schedule issued by the Government on the CDCC Scheme Website. Co-payments should be paid directly by the patients to the family doctor, AH Service Provider or Investigation Service Sites/Centres.

Depending on the patient’s clinical needs and agreement with their family doctor, patients may receive services outside the scope of the CDCC Scheme. Any fees incurred for such services must be paid by the patients out-of-pocket.

Medical fee waiver is not applicable to the CDCC Scheme. Patients who are HA staff, civil service eligible persons, or individuals entitled to medical fee waivers when receiving services at HA are still required to pay the same co-payments as all other participants under the CDCC Scheme. However, eligible patients may use their Health Care Vouchers under the Elderly Health Care Voucher Scheme (EHVS) to settle any co-payments charged by family doctor and other health care professionals for service(s) under the CDCC Scheme, provided that the relevant healthcare service providers have participated in the EHVS and accept such form of payment.

Interested patients can select a suitable family doctor, according to their own choice, by searching the website of the CDCC Scheme, which provides the list of Family Doctors with their essential information including practice district, service charge under the CDCC Scheme and participation in other Government subsidised primary healthcare programme e.g., Elderly Healthcare Voucher Scheme.

The objective of the CDCC Scheme is to provide targeted subsidised services through a "Family Doctor for All" and multi-disciplinary public-private partnership model to enable eligible public to receive screening and management of target chronic diseases in the private healthcare sector. Generally, participation in the CDCC Scheme will not affect the other healthcare services that patients are currently receiving from the HA or DH such as emergency services and other specialist services.

To support and empower family doctors in long-term management of patients, the Government has developed a bi-directional referral mechanism with the HA involving seven HA Clusters under the CDCC Scheme. Based on the pre-defined criteria, if a patient is assessed by a family doctor as having clinical needs (such as undesirable disease control or complications), the family doctor can arrange for the patient to receive a one-off specialist consultation at a designated Medicine Specialist Out-patient Clinic of the HA according to the guidelines. The patient can obtain clinical advice on a care plan, which he/ she can then continue to follow up with the family doctor. This special arrangement is not regarded as a specialist out-patient referral nor follow-up consultation, and each attendance is charged at a standardised fee of $250. The HA in general would not arrange follow-up appointments for patients. In the event that drug prescription is required for patients, a charge of $20 will be applied per prescribed drug item (4 weeks as chargeable unit). Medical fee waiver is not applicable to this arrangement, and same fees apply to patients who are HA staff, civil service eligible persons, and other individuals entitled to medical fee waivers when receiving services at HA.

Patients are required to arrange withdrawal from the CDCC Scheme at the DHC/Es. However, individuals are recommended to pay attention to their own health conditions and consult healthcare professionals for appropriate treatment according to their needs.

Family doctors are required to meet the following criteria for enrolment in the CDCC Scheme:

1. Practising in a private healthcare facility;
2. Being included in the general register in accordance to Section 14 or Section 14A of the Medical Registration Ordinance (Cap. 161 of the laws of Hong Kong) and holding a valid practising certificate;
3. Being a healthcare provider enrolled in the Electronic Health System (eHealth); and
4. Being listed in the Primary Care Directory (PCD).

    

Interested family doctors may enrol in the CDCC Scheme either by invitation from the Government or through their own volition online through the eHealth.

For further details, please visit the official website of CDCC Scheme or contact the enquiry hotline at 2300 7300. The hotline operates from Monday to Saturday, 9:00am to 9:00pm. If the line is busy or if a call is made outside of operating hours, you may leave a voicemail, and staff will return your call as soon as possible during office hours.

The GOPC PPP is launched by the Government, through the Hospital Authority (HA), aiming to: 
(a) provide choice to patients for receiving primary care service from the private sector in their community; 
(b) enhance patient access to primary care service; 
(c) promote the family doctor concept; 
(d) help HA manage demand for general/specialist outpatient service; and 
(e) foster the development of the territory-wide Electronic Health System (eHealth).

Under the GOPC PPP, each patient will receive:

• Up to 10 subsidised visits to the participating service providers (PSPs) per year, covering both chronic and episodic illnesses;
• Drugs for treating their chronic conditions and episodic illnesses immediately from the PSPs at their clinics; and
• Upon PSPs’ referral, to receive laboratory and other investigation services at the designated laboratory services provider and X-ray examination at HA

Under the GOPC PPP, at each visit paid by a participating patient, the PSP clinic shall use “Register Attendance” function built in the GOPC PPP IT platform to take attendance with either one of the following methods:

• Smart-ID: Insert patient’s Hong Kong Identity Card into the eHealth card reader;
• One-time password: Enter a real-time passcode received by patient into IT platform; or
• Attendance sheet: Print out an attendance sheet from the IT platform and ask both the patient and the PSP to confirm attendance by signing on the attendance sheet. Then, fax the completed attendance sheet to the IT platform for vetting by the Programme Office.

 Only consultation records with a valid patient attendance record are eligible for reimbursement of service fees.

Yes. Under the GOPC PPP, beyond the 10 subsidised visits, patients have to pay out-of-pocket in full for the fees charged by the PSP. Those who participate in the Elderly Health Care Voucher Scheme can pay for non-GOPC PPP services / treatments from their Health Care Voucher accounts.

Yes, under the GOPC PPP, participating patients can seek care for both chronic and episodic illnesses at a given subsidised visit, and receive drugs for treating the corresponding illnesses.

Under the GOPC PPP, in accordance with individual patient’s clinical indication(s), PSPs will provide those drugs covered under the “List of Specified Drugs” based on the patient’s designated referred specialty, with charges of $5 per item (4 weeks as chargeable unit) to patients. If PSPs prescribes non‑programme drugs for the treatment of episodic illnesses, and the duration does not exceed three days, no charges are required to be paid by the patient. Patients eligible for a full medical fee waiver under the programme are not required to pay any fees for programme‑listed drugs.

Other than such conditions, PSPs may charge for further medications prescribed upon mutual agreement with individual patient.

(For details of the “List of Specified Drugs”, PSPs can refer to the GOPC PPP Booklet of Schedules posted on the Programme’s website (http://www.ha.org.hk/ppp/gopcppp).)

Under the GOPC PPP, for the “List of Specified Drugs”, PSPs may use their own drugs or purchase from designated drug suppliers at specified prices. For the latter, the GOPC PPP IT platform has been enhanced such that PSPs can make orders for programme drugs, view the order status, check the remaining balance and review past orders via the IT platform. 

Any PSP can order programme drugs via the IT platform after he/she has enrolled his/her first patient under the GOPC PPP.  A “Starter Pack” comprising of all drug items under the “List of Specified Drugs” will then be available for purchase by the PSP. Upon depletion of the Starter Pack, subsequent replenishment of each drug item will be based on the number of patients prescribed with the drug, with a buffer quantity. It is important for PSPs to accurately input prescription records for each consultation into the IT platform to facilitate the system to deduce the quantity of drugs available for ordering.

Under the GOPC PPP, participating patients will receive drugs for treating their chronic conditions and episodic illnesses immediately from the PSPs at their clinics. PSPs may use their own drugs or purchase the drugs under the “List of Specified Drugs” from designated suppliers at specified prices. Individual patients may also receive drugs outside the scope of GOPC PPP provided by PSPs at their own expenses upon mutual agreement between the patients and PSPs.

Under the GOPC PPP, subject to a patient’s clinical need and under mutual agreement, the PSPs may prescribe an appropriate duration of drugs to the patient.

Upon referral by the PSPs, participating patients can receive laboratory and other investigation services at designated laboratory service providers, as well as X-ray examination at HA. All investigation services under the GOPC PPP are provided to patients free of charge, except for Thyroglobulin or Anti-thyroglobulin Antibody tests, which require a patient co-payment of $50 per item. Medical fee waiver arrangements remain applicable.

Under mutual agreement, individual patients may receive further services provided by the PSPs at their own expense outside the scope of the GOPC PPP.

The addresses of the designated laboratory service providers are displayed on the website of the GOPC PPP for public information. Upon referral by their PSPs, patients can receive relevant laboratory and other investigation services at:

1. Scheme Participants can receive relevant laboratory and other investigation services at laboratory service providers, which are designated by Government.

    

2. Some PSPs may opt to provide blood taking and specimen collection services to Scheme Participants.

   PSPs can collect a mutually agreed value-added service fee for the blood taking and specimen collection services from the patient.

Patients can choose from any of the service points:

1. Any of the service locations provided by the designated laboratory service providers
2. PSP’s clinic

   Some PSPs may opt to provide blood taking and specimen collection services to Scheme Participants.

The service points and service hours can be found via the QR Code on the request note issued by the PSPs or on the website of the GOPC PPP.

Request note issued on or before 5 November 2025

• There are two designated laboratory service providers.
• Each PSP's clinic will be assigned to one of these providers according to the tender specifications with due consideration to the clinics' district location.

Request note issued on or after 6 November 2025

• There are two designated laboratory service providers. Patients can choose any service locations provided by the two laboratory service providers for the laboratory and other investigation services.
• If PSPs opt to provide blood taking and specimen collection services, they can select one of the laboratory service providers to provide courier service for picking up the specimen and the subsequent laboratory services.

PSPs should select one of the designated laboratory service providers for each service location to facilitate specimen transport and laboratory testing. To enhance efficiency and accuracy in specimen handling, we recommend PSPs to establish a long-term partnership with the chosen designated laboratory service provider.

If a change in designated laboratory service provider partnership is necessary, please ensure a smooth handover and the patients' test specimens are delivered accurately.

Patients can use the Elderly Health Care Voucher to pay for the value-added service fees. The charges will be reflected in the SMS confirmation sent to patients.

There will be no subsidy provided for ECGs conducted in PSP clinics. Subsidised ECG services must be performed at the service site of the designated laboratory service providers.

The turnaround time for laboratory and other investigation services may vary depending on the laboratory and other investigation item(s) and the designated laboratory services provider conducting the test(s).  Generally, the test(s) may be completed within a few days. The PSPs will receive the laboratory and other investigation results electronically through IT Platform once available.

Subject to the mutual arrangement between patients and PSPs, patients may pay out-of-pocket to choose to receive laboratory and other investigation services from service providers other than the Government designated laboratory services providers. patients will have to pay the full costs of laboratory and other investigation services incurred without Government subsidy.

Under the GOPC PPP, if clinically indicated, PSPs may refer their patients to HA for further assessment and treatment. PSPs may contact Cluster PPP Office for further information.

PSPs may choose not to accept patients referred to them. However, they should inform the Cluster PPP Office as soon as possible, so other appropriate arrangements can be made for the concerned patient.

Yes, PSPs can inform the Programme Office of their maximum capacity on patient enrolment under the GOPC PPP, and stop receiving new patients when the maximum capacity is reached.

Under the GOPC PPP, with effect from 1 July 2023, for service provision, PSPs will receive a maximum total of $3,660 per patient per year, covering a maximum of 10 consultations. This includes a consultation fee of $150 and a drug fee of $5 per programme drug item (4 weeks as chargeable unit), with both fees aligned with HA FMC fees set out in the Gazette, to be paid by the patients to the PSPs after each consultation.

A participating patient who is eligible for a waiver under the criteria set out in HA’s website relating to the GOPC PPP (http://www.ha.org.hk/ppp/gopcppp) may be entitled to partial or full waiver of the consultation and drug fees when he/she attends the PSP under the GOPC PPP. In such cases, the HA will bear the relevant fee.

Under the GOPC PPP, PSPs will receive the relevant service fees from the HA on a reimbursement basis. Claims for consultations will be paid directly to the PSP’s designated bank account on monthly basis, whilst the medication subsidy would be paid on a quarterly basis. PSPs can verify and submit claims via the GOPC PPP IT Platform to the HA for processing. Claims submitted on or before the cut-off date (i.e. 10th of every calendar month) will be processed in the same month, while outstanding claims will be saved in the GOPC PPP IT system for future submission until reimbursed.

Under the GOPC PPP, participating patients are required to pay co-payments for consultation, programme drugs, and certain investigation services, in line with the HA FMC fees set out in the Gazette. The consultation fee is $150 per visit, and the programme drug fee is $5 per item (with 4 weeks as chargeable unit). All basic laboratory and investigation items are provided to patients free of charge; however, a co-payment of $50 per item applies to Thyroglobulin and Anti-thyroglobulin Antibody tests.

A participating patient who is eligible for a waiver under the criteria set out in HA’s website relating to the Programme (http://www.ha.org.hk/ppp/gopcppp) may be entitled to partial or full waiver of the co-payment when he/she attends the PSPs or receives services at the designated private laboratories under the GOPC PPP. Under mutual agreement, individual patients may receive further services and treatments provided by the PSPs at their own expense outside the scope of the GOPC PPP. 

Under the GOPC PPP, participating patients can receive subsidised medical consultation once a day covering the care on chronic or episodic illnesses or both. Additional consultation(s) in any single day is/are not covered under the scope of the GOPC PPP. Yet, individual patients may receive additional service(s) or treatments at their own expenses upon mutual agreement with their PSPs.

Under the GOPC PPP, Elderly Health Care Vouchers may only be used to pay for non-GOPC PPP services from patients’ Health Care Voucher accounts.

Under the GOPC PPP, PSPs may arrange relieving doctors during their absence. The relieving doctors shall also enrol in the eHealth. 

To facilitate continuity of patient care, all participating patients and PSPs under the GOPC PPP are required to participate in the eHealth, to enable clinical information sharing between the private and the public sectors.

Under the GOPC PPP, PSPs are required to enter patients’ basic clinical information (e.g. blood pressure and pulse, etc.), as the case may be, for chronic visits to the GOPC PPP IT Platform within 3 calendar days after each consultation. PSPs are also encouraged to make use of the GOPC PPP IT Platform for other clinical documentation such as drugs prescription or other additional services provided. After 3 calendar days, PSPs are required to submit an unlock consultation request for inputting or editing the consultations.

Under the GOPC PPP, during the fixed period(s) as specified by HA from time to time, HA will subsidise each patient with two additional subsidised visit quotas. The additional quotas will apply to the first two visits made by the patients within the fixed period, where patient can, subject to the T&Cs, attend PSP clinic for consultations on follow up of the designated chronic illnesses and/or on episodic illnesses (acute or chronic) without deducting their 10 annual quotas. For each consultation visit under the additional quotas, PSPs will receive the same service fee as for the annual quotas, which includes the patient co-payment for consultation and programme drug fees (subject to applicable waivers for individual patient).

During the specified period, an anti-viral drug, Tamiflu, will be included as an add-on medication under the GOPC PPP for prescription to patients if so required by the patients’ clinical condition. Each patient will be subsidised with up to one course of Tamiflu during each specified period and will be required to pay a programme drug fee of $5 (4 weeks as chargeable unit). 

Other than the conditions stated above, individual patients may also receive further services and treatment provided by PSP at their own expenses under mutual agreement.

Under the GOPC PPP, PSPs shall prescribe and dispense Tamiflu to patients as clinically indicated from their own drug stock and input relevant prescription details in the GOPC PPP IT platform. Prescription entitled to drug replenishment will be reflected in the orderable quantity for stock replenishment on the 4th of the following month. PSPs can place one confirmed order with the supplier via the GOPC PPP IT platform every month with the maximum quantity prefilled. The processing of drug orders and arrangement of delivery will take place after the 10th of each month and this will not incur any delivery charges on the PSP. Order placed after the monthly cut-off will be processed in the next month.

The maximum quantity that PSP can order is up to one course of Tamiflu for each patient during the subsidised visits made in the specified period. Tamiflu prescription falls outside the condition stated above will not be entitled to drug replenishment.